Valtrex®
valacyclovir · oral tablet
Antiviral
Approved uses
Herpes zoster in immunocompetent adults, including herpes zoster ophthalmicus
1 gram three times daily for 7 days, started at the earliest sign or symptom; most effective when started within 48 hours of rash onset, and efficacy after 72 hours is not established; efficacy and safety in disseminated herpes zoster are not established
Start as soon as possible after diagnosis; the label has no data on treatment begun more than 72 hours after rash onset
Cold sores (herpes labialis), age 12 and over
2 grams every 12 hours for one day
Genital herpes, initial or recurrent episode, and suppression
Initial episode (immunocompetent adults): 1 gram twice daily for 10 days, most effective within 48 hours of onset; efficacy after 72 hours is not established. Recurrent episode (immunocompetent adults): 500 mg twice daily for 3 days, started at the first sign or symptom; efficacy after 24 hours is not established. Suppression (adults): 1 gram once daily with normal immune function, or 500 mg once daily in immunocompetent patients with 9 or fewer recurrences a year (500 mg twice daily in HIV-1 infection with a CD4+ count of 100 cells/mm3 or more); not established beyond 1 year in immunocompetent patients or 6 months in HIV-1 infection.
Chickenpox, immunocompetent patients aged 2 to under 18
20 mg/kg 3 times daily for 5 days, not to exceed 1 gram 3 times daily; start within 24 hours of rash onset
Reduction of genital herpes transmission, immunocompetent adults
500 mg once daily for the source partner with 9 or fewer recurrences a year, with safer sex practices; efficacy is not established beyond 8 months in discordant couples, or in people with multiple partners or non-heterosexual couples
Contraindications
Demonstrated clinically significant hypersensitivity reaction, such as anaphylaxis or severe cutaneous adverse reactions (SCARs), to valacyclovir, acyclovir or any component of the formulation
Valacyclovir tablets, 500 mg (unscored) and 1 gram (partially scored), each in bottles of 30 and 90
Inhibits viral DNA polymerase, preventing viral replication.
Warnings & Precautions
- TTP/HUS: thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, in some cases fatal, has occurred in advanced HIV-1 disease and in allogeneic bone marrow and renal transplant recipients taking 8 grams a day in clinical trials; stop at once if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS occur.
- Acute renal failure: cases have been reported in elderly patients with or without reduced renal function, in renal disease at higher-than-recommended doses for their level of renal function, with other nephrotoxic drugs, and without adequate hydration. Use caution in elderly patients and with potentially nephrotoxic drugs, and maintain adequate hydration for all patients. In acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored.
- Renal impairment: reduce the dose when creatinine clearance is below 50 mL/min for herpes zoster and cold sores, and below 30 mL/min for genital herpes. For herpes zoster, 1 gram every 12 hours at 30-49, 1 gram every 24 hours at 10-29, 500 mg every 24 hours below 10.
- Central nervous system effects: agitation, hallucinations, confusion, delirium, seizures and encephalopathy have been reported in both adult and pediatric patients with or without reduced renal function, and in renal disease at higher-than-recommended doses for their level of renal function; elderly patients are more likely to have them. Stop the drug if they occur.
- Severe cutaneous adverse reactions: AGEP, DRESS, SJS and TEN have been reported during postmarketing experience; stop at once if a painful rash with mucosal involvement or a progressive severe rash develops, and closely monitor clinical status and initiate appropriate therapy.
Common Side Effects
The most common adverse reactions reported in at least 1 indication by greater than 10% of adult subjects treated with valacyclovir and observed more frequently than with placebo are headache, nausea, and abdominal pain. The only adverse reaction reported in greater than 10% of pediatric subjects was headache.
Pregnancy: Clinical data over several decades with valacyclovir and its metabolite, acyclovir, in pregnant women have not identified a drug-associated risk of major birth defects. There are insufficient data on miscarriage or adverse maternal or fetal outcomes, and untreated herpes simplex during pregnancy carries risks to the fetus.
Lactation: Acyclovir is present in human milk after oral valacyclovir; a 500-mg maternal dose twice daily would provide a breastfed child an oral acyclovir dosage of approximately 0.6 mg/kg/day. Consider the benefits of breastfeeding along with the mother's clinical need for valacyclovir and any potential adverse effects on the breastfed child.
Indicated for cold sores from age 12 and for chickenpox from age 2 to under 18. Efficacy and safety are not established under 12 for cold sores, under 18 for genital herpes or herpes zoster, under 2 for chickenpox, or for suppression after neonatal HSV infection.